CAR-T是一种过继细胞免疫治疗方法，通过改造患者自身的T细胞，使其表达能够识别肿瘤抗原的嵌合抗原受体，从而增强T细胞对肿瘤细胞的杀伤作用。CAR-T治疗首先从患者体内提取T细胞，经过基因工程技术改造后表达嵌合抗原受体，然后在体外扩增后回输给患者。改造后的T细胞能够特异性识别并攻击表达相应抗原的肿瘤细胞，发挥强大的...
[1]https://www.onclive.com/view/fda-approves-cilta-cel-for-r-r-multiple-myeloma-who-have-received-at-least-one-prior-line-of-therapy
[1]Zhang X,et al.CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies. Front Immunol. 2023 Feb 20;14:1101495. doi: 10.3389/fimmu.2023.1101495. https://www.ncbi.nlm.nih.gov/pmc/articles/PM...
参考资料 [1]Zhang X,et al.CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies. Front Immunol. 2023 Feb 20;14:1101495. doi: 10.3389/fimmu.2023.1101495.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986336/ [2]Rendo MJ,et al.CAR T-Cell Therapy for Patie...
总的来说,研究者认为还需要关于安全性和有效性评估、人群和试验设计的统一报告信息。未来在对MM CAR-T细胞治疗的研究中,筛选患者、设计新产品和确定治疗算法等因素,都应纳入考虑范畴。 参考资料: Development of CAR-T cell therapies for multiple myeloma 关键词: 多发性骨髓瘤治疗靶向 45 打赏...
Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better? Leukemia. 2020 Jan;34(1):21-34. doi: 10.1038/s41375-019-0669-4. Epub 2019 Nov 28. PMID: 31780814.Feng D, Sun J. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple ...
1.Oricell Therapeutics’ GPRC5D-Targeted CAR-T Therapy, OriCAR-017, Receives FDA Fast Track Designation for Relapsed/Refractory Multiple Myeloma 2.OriCAR-017, a novel GPRC5D-targeting CAR-T, in patients with relapsed/refractory multiple myeloma: Long term follow-up results of phase 1 study (PO...
[1]https://endpts.com/cellectis-slammed-as-fda-puts-a-clinical-hold-on-one-of-their-off-the-shelf-car-ts-for-multiple-myeloma/ [2]https://endpts.com/in-staggering-setback-toxic-reaction-kills-cellectis-first-car-t-patient-forcing-trial-halt/ ...
备注: R/R: Relapsed/Refractory复发/难治; ALL: Acute Lymphoblastic Leukemia急性淋巴细胞白血病; MM: Multiple Myeloma多发性骨髓瘤; NHL: Non-Hodgkin's Lymphoma非霍奇金淋巴瘤; AML: Acute Myeloid Leukemia急性髓系白血病 1 单靶点CAR-T疗法与双靶点CAR-T 疗法对比 单靶点与双靶点CAR-T疗法的部分特点比较...
[2]Parikh RH, Lonial S. Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice. CA Cancer J Clin. 2023 May-Jun;73(3):275-285. doi: 10.3322/caac.21771. Epub 2023 Jan 10. PMID: 36627265. ...